PortalPublikationenPatterns of Disease Progression and Outcome of Patients With...

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Standard

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. / Terbuch, Angelika; Posch, Florian; Bauernhofer, Thomas; Jost, Philipp Jakob; Partl, Richard; Stranzl-Lawatsch, Heidi; Baciarello, Giulia; Fizazi, Karim; Giannatempo, Patrizia; Verzoni, Elena; Sweeney, Christopher; Ravi, Praful; Tran, Ben; Basso, Umberto; White, Jeff; Vincenzi, Bruno; Oing, Christoph; Cutuli, Hernan Javier; Dieckmann, Klaus Peter; Gamulin, Marija; Chovanec, Michal; Fankhauser, Christian Daniel; Heidenreich, Axel; Mohamad, Osama; Thibault, Constance; Fischer, Stefanie; Gillessen, Silke; International Germ Cell Cancer Collaborative Group.

in: INT J RADIAT ONCOL, Jahrgang 113, Nr. 4, 15.07.2022, S. 825-832.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Terbuch, A, Posch, F, Bauernhofer, T, Jost, PJ, Partl, R, Stranzl-Lawatsch, H, Baciarello, G, Fizazi, K, Giannatempo, P, Verzoni, E, Sweeney, C, Ravi, P, Tran, B, Basso, U, White, J, Vincenzi, B, Oing, C, Cutuli, HJ, Dieckmann, KP, Gamulin, M, Chovanec, M, Fankhauser, CD, Heidenreich, A, Mohamad, O, Thibault, C, Fischer, S, Gillessen, S & International Germ Cell Cancer Collaborative Group 2022, 'Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy', INT J RADIAT ONCOL, Jg. 113, Nr. 4, S. 825-832. https://doi.org/10.1016/j.ijrobp.2022.03.021

APA

Terbuch, A., Posch, F., Bauernhofer, T., Jost, P. J., Partl, R., Stranzl-Lawatsch, H., Baciarello, G., Fizazi, K., Giannatempo, P., Verzoni, E., Sweeney, C., Ravi, P., Tran, B., Basso, U., White, J., Vincenzi, B., Oing, C., Cutuli, H. J., Dieckmann, K. P., ... International Germ Cell Cancer Collaborative Group (2022). Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. INT J RADIAT ONCOL, 113(4), 825-832. https://doi.org/10.1016/j.ijrobp.2022.03.021

Vancouver

Terbuch A, Posch F, Bauernhofer T, Jost PJ, Partl R, Stranzl-Lawatsch H et al. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. INT J RADIAT ONCOL. 2022 Jul 15;113(4):825-832. https://doi.org/10.1016/j.ijrobp.2022.03.021

Bibtex

@article{40f194cd8cbc48d49a80cfcde0c4ef79,
title = "Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy",
abstract = "PURPOSE: Radiation therapy is a possible treatment strategy for patients with testicular seminoma after orchiectomy in clinical stage I or II disease. Little is known about the outcome of patients who experience a relapse after radiation therapy.METHODS AND MATERIALS: Data from 61 patients who relapsed after adjuvant or curative radiation therapy from 17 centers in 11 countries were collected and retrospectively analyzed. Primary outcomes were disease-free and overall survival. Secondary outcomes were time to relapse, stage at relapse, treatment for relapse, and rate of febrile neutropenia during chemotherapy for relapse.RESULTS: With a median follow-up of 9.9 years (95% confidence interval [CI], 7.5-10.9), we found a 5-year disease-free survival of 90% (95% CI, 79-95) and a 5-year overall survival of 98% (95% CI, 89-100). Sixty-six percent of patients had stage III disease at time of relapse and 93% of patients fell into the good prognosis group per the International Germ Cell Cancer Collaborative Group classification. The median time to relapse after radiation therapy was 15.6 months (95% CI, 12-23). Twenty-two (36%) patients relapsed more than 2 years after radiation therapy and 7 (11.5%) patients relapsed more than 5 years after radiation therapy. One-third of relapses was detected owing to patients' symptoms, whereas two-thirds of relapses were detected during routine follow-up. The majority (93%) of cases were treated with cisplatin-based chemotherapy. The rate of febrile neutropenia during chemotherapy was 35%. Five patients experienced a second relapse. At last follow-up, 55 patients (90%) were alive without disease. Only 1 patient died owing to disease progression.CONCLUSIONS: Cisplatin-based chemotherapy for patients with seminoma who have relapsed after treatment with radiation therapy alone leads to excellent outcomes. Patients and physicians should be aware of possible late relapses after radiation therapy.",
author = "Angelika Terbuch and Florian Posch and Thomas Bauernhofer and Jost, {Philipp Jakob} and Richard Partl and Heidi Stranzl-Lawatsch and Giulia Baciarello and Karim Fizazi and Patrizia Giannatempo and Elena Verzoni and Christopher Sweeney and Praful Ravi and Ben Tran and Umberto Basso and Jeff White and Bruno Vincenzi and Christoph Oing and Cutuli, {Hernan Javier} and Dieckmann, {Klaus Peter} and Marija Gamulin and Michal Chovanec and Fankhauser, {Christian Daniel} and Axel Heidenreich and Osama Mohamad and Constance Thibault and Stefanie Fischer and Silke Gillessen and {International Germ Cell Cancer Collaborative Group}",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = jul,
day = "15",
doi = "10.1016/j.ijrobp.2022.03.021",
language = "English",
volume = "113",
pages = "825--832",
journal = "INT J RADIAT ONCOL",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

AU - Terbuch, Angelika

AU - Posch, Florian

AU - Bauernhofer, Thomas

AU - Jost, Philipp Jakob

AU - Partl, Richard

AU - Stranzl-Lawatsch, Heidi

AU - Baciarello, Giulia

AU - Fizazi, Karim

AU - Giannatempo, Patrizia

AU - Verzoni, Elena

AU - Sweeney, Christopher

AU - Ravi, Praful

AU - Tran, Ben

AU - Basso, Umberto

AU - White, Jeff

AU - Vincenzi, Bruno

AU - Oing, Christoph

AU - Cutuli, Hernan Javier

AU - Dieckmann, Klaus Peter

AU - Gamulin, Marija

AU - Chovanec, Michal

AU - Fankhauser, Christian Daniel

AU - Heidenreich, Axel

AU - Mohamad, Osama

AU - Thibault, Constance

AU - Fischer, Stefanie

AU - Gillessen, Silke

AU - International Germ Cell Cancer Collaborative Group

N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2022/7/15

Y1 - 2022/7/15

N2 - PURPOSE: Radiation therapy is a possible treatment strategy for patients with testicular seminoma after orchiectomy in clinical stage I or II disease. Little is known about the outcome of patients who experience a relapse after radiation therapy.METHODS AND MATERIALS: Data from 61 patients who relapsed after adjuvant or curative radiation therapy from 17 centers in 11 countries were collected and retrospectively analyzed. Primary outcomes were disease-free and overall survival. Secondary outcomes were time to relapse, stage at relapse, treatment for relapse, and rate of febrile neutropenia during chemotherapy for relapse.RESULTS: With a median follow-up of 9.9 years (95% confidence interval [CI], 7.5-10.9), we found a 5-year disease-free survival of 90% (95% CI, 79-95) and a 5-year overall survival of 98% (95% CI, 89-100). Sixty-six percent of patients had stage III disease at time of relapse and 93% of patients fell into the good prognosis group per the International Germ Cell Cancer Collaborative Group classification. The median time to relapse after radiation therapy was 15.6 months (95% CI, 12-23). Twenty-two (36%) patients relapsed more than 2 years after radiation therapy and 7 (11.5%) patients relapsed more than 5 years after radiation therapy. One-third of relapses was detected owing to patients' symptoms, whereas two-thirds of relapses were detected during routine follow-up. The majority (93%) of cases were treated with cisplatin-based chemotherapy. The rate of febrile neutropenia during chemotherapy was 35%. Five patients experienced a second relapse. At last follow-up, 55 patients (90%) were alive without disease. Only 1 patient died owing to disease progression.CONCLUSIONS: Cisplatin-based chemotherapy for patients with seminoma who have relapsed after treatment with radiation therapy alone leads to excellent outcomes. Patients and physicians should be aware of possible late relapses after radiation therapy.

AB - PURPOSE: Radiation therapy is a possible treatment strategy for patients with testicular seminoma after orchiectomy in clinical stage I or II disease. Little is known about the outcome of patients who experience a relapse after radiation therapy.METHODS AND MATERIALS: Data from 61 patients who relapsed after adjuvant or curative radiation therapy from 17 centers in 11 countries were collected and retrospectively analyzed. Primary outcomes were disease-free and overall survival. Secondary outcomes were time to relapse, stage at relapse, treatment for relapse, and rate of febrile neutropenia during chemotherapy for relapse.RESULTS: With a median follow-up of 9.9 years (95% confidence interval [CI], 7.5-10.9), we found a 5-year disease-free survival of 90% (95% CI, 79-95) and a 5-year overall survival of 98% (95% CI, 89-100). Sixty-six percent of patients had stage III disease at time of relapse and 93% of patients fell into the good prognosis group per the International Germ Cell Cancer Collaborative Group classification. The median time to relapse after radiation therapy was 15.6 months (95% CI, 12-23). Twenty-two (36%) patients relapsed more than 2 years after radiation therapy and 7 (11.5%) patients relapsed more than 5 years after radiation therapy. One-third of relapses was detected owing to patients' symptoms, whereas two-thirds of relapses were detected during routine follow-up. The majority (93%) of cases were treated with cisplatin-based chemotherapy. The rate of febrile neutropenia during chemotherapy was 35%. Five patients experienced a second relapse. At last follow-up, 55 patients (90%) were alive without disease. Only 1 patient died owing to disease progression.CONCLUSIONS: Cisplatin-based chemotherapy for patients with seminoma who have relapsed after treatment with radiation therapy alone leads to excellent outcomes. Patients and physicians should be aware of possible late relapses after radiation therapy.

U2 - 10.1016/j.ijrobp.2022.03.021

DO - 10.1016/j.ijrobp.2022.03.021

M3 - SCORING: Journal article

C2 - 35461737

VL - 113

SP - 825

EP - 832

JO - INT J RADIAT ONCOL

JF - INT J RADIAT ONCOL

SN - 0360-3016

IS - 4

ER -